615 related articles for article (PubMed ID: 28855159)
1. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.
Tielemans SMAJ; de Melker HE; Hahné SJM; Boef AGC; van der Klis FRM; Sanders EAM; van der Sande MAB; Knol MJ
BMJ; 2017 Aug; 358():j3862. PubMed ID: 28855159
[No Abstract] [Full Text] [Related]
2. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H
JAMA; 2014 Feb; 311(8):826-35. PubMed ID: 24570246
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections: A nationwide register based cohort study.
Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H
Vaccine; 2016 Dec; 34(50):6172-6180. PubMed ID: 27840013
[TBL] [Abstract][Full Text] [Related]
4. Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'.
Rieckmann A; Hærskjold A; Benn CS; Aaby P; Lange T; Sørup S
Int J Epidemiol; 2019 Dec; 48(6):2026-2038. PubMed ID: 31062020
[TBL] [Abstract][Full Text] [Related]
5. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
7. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
Rennels MB; Englund JA; Bernstein DI; Losonsky GA; Anderson EL; Pichichero ME; Munoz FM; Wolff MC
Pediatr Infect Dis J; 2000 May; 19(5):417-23. PubMed ID: 10819337
[TBL] [Abstract][Full Text] [Related]
8. Age-appropriate versus up-to-date coverage of routine childhood vaccinations among young children in Israel.
Stein-Zamir C; Israeli A
Hum Vaccin Immunother; 2017 Sep; 13(9):2102-2110. PubMed ID: 28696824
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
[TBL] [Abstract][Full Text] [Related]
10. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL; Hutter GE
Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
[TBL] [Abstract][Full Text] [Related]
12. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
Dolhain J; Janssens W; Dindore V; Mihalyi A
Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537
[TBL] [Abstract][Full Text] [Related]
13. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
[TBL] [Abstract][Full Text] [Related]
14. How are children who are delayed in the Childhood Vaccination Programme vaccinated: A nationwide register-based cohort study of Danish children aged 15-24 months and semi-structured interviews with vaccination providers.
Pedersen KB; Holck ME; Jensen AKG; Suppli CH; Benn CS; Krause TG; Sørup S
Scand J Public Health; 2020 Feb; 48(1):96-105. PubMed ID: 30024308
[No Abstract] [Full Text] [Related]
15. Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age.
Kiely M; Billard MN; Toth E; Zafack JG; Landry M; Skowronski DM; De Serres G
Vaccine; 2018 Oct; 36(45):6688-6694. PubMed ID: 30269915
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study.
Dhingra MS; Namazova-Baranova L; Arredondo-Garcia JL; Kim KH; Limkittikul K; Jantarabenjakul W; Perminova O; Kobashi IAR; Bae CW; Ojeda J; Park J; Chansinghakul D; B'Chir S; Neveu D; Bonaparte M; Jordanov E
Epidemiol Infect; 2021 Apr; 149():e90. PubMed ID: 33814028
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
Pancharoen C; Chotpitayasunondh T; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2012 May; 43(3):687-98. PubMed ID: 23077849
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States.
Greenberg DP; Doemland M; Bettinger JA; Scheifele DW; Halperin SA; ; Waters V; Kandola K
Pediatr Infect Dis J; 2009 Jun; 28(6):521-8. PubMed ID: 19436236
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
[TBL] [Abstract][Full Text] [Related]
20. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
